Bristol Myers Squibb balance sheet
At the end of fiscal 2025, Bristol Myers Squibb had total assets of $90.04bn, total liabilities of $71.53bn and shareholders' equity of $18.47bn. It held $10.21bn in cash against $47.09bn of debt: net debt of $36.88bn.
Balance sheet
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 7.7 | 5.0 | 5.8 | 1.7 | 3.6 | 5.6 | 2.4 | 4.2 | 5.4 | 6.9 | 12.3 | 14.5 | 14.0 | 9.1 | 11.5 | 10.3 | 10.2 | 9.6 |
| Receivables | 1.9 | 2.0 | 2.3 | 1.7 | 1.7 | 2.1 | 2.9 | 3.8 | 4.3 | 4.6 | 6.5 | 7.2 | 8.0 | 8.2 | 8.9 | 9.0 | 9.6 | 9.2 |
| Inventory | 1.4 | 1.2 | 1.4 | 1.7 | 1.5 | 1.6 | 1.2 | 1.2 | 1.2 | 1.2 | 4.3 | 2.1 | 2.1 | 2.3 | 2.7 | 2.6 | 2.7 | 2.7 |
| Total current assets | 14.0 | 13.3 | 15.3 | 9.5 | 18.9 | 14.6 | 10.4 | 13.7 | 14.9 | 17.7 | 29.4 | 30.2 | 33.3 | 27.3 | 31.8 | 29.8 | 29.4 | 29.8 |
| Goodwill | 5.2 | 5.2 | 5.6 | 7.6 | 7.1 | 7.0 | 6.9 | 6.9 | 6.9 | 6.5 | 22.5 | 20.5 | 20.5 | 21.1 | 21.2 | 21.7 | 21.8 | 21.7 |
| Total assets | 31.0 | 31.1 | 33.0 | 35.9 | 38.6 | 33.7 | 31.7 | 33.7 | 33.6 | 35.0 | 129.9 | 118.5 | 109.3 | 96.8 | 95.2 | 92.6 | 90.0 | 88.8 |
| Accounts payable | 1.7 | 2.0 | 2.6 | 2.2 | 2.6 | 2.5 | 1.6 | 1.7 | 2.2 | 1.9 | 2.4 | 2.7 | 2.9 | 3.0 | 3.3 | 3.6 | 3.6 | 4.6 |
| Deferred revenue (current) | 0.2 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total current liabilities | 6.3 | 6.7 | 7.8 | 8.3 | 12.4 | 8.5 | 8.0 | 8.8 | 9.6 | 10.7 | 18.3 | 19.1 | 21.9 | 21.9 | 22.3 | 23.8 | 23.4 | 18.8 |
| Short-term debt | 0.2 | 0.1 | 0.1 | 0.8 | 0.4 | 0.6 | 0.1 | 1.0 | 1.0 | 1.7 | 3.3 | 2.3 | 4.9 | 4.3 | 3.1 | 2.0 | 2.3 | 1.0 |
| Long-term debt | 6.1 | 5.3 | 5.4 | 6.6 | 8.0 | 7.2 | 6.6 | 5.7 | 7.0 | 5.6 | 43.4 | 48.3 | 39.6 | 35.1 | 36.7 | 47.6 | 42.9 | 41.8 |
| Total debt | 6.4 | 5.4 | 5.5 | 8.1 | 8.4 | 7.8 | 6.7 | 6.7 | 8.0 | 8.6 | 49.5 | 52.7 | 49.3 | 43.2 | 42.6 | 51.5 | 47.1 | 43.6 |
| Total liabilities | 16.2 | 15.4 | 17.1 | 22.3 | 23.4 | 18.8 | 17.3 | 17.4 | 21.7 | 20.9 | 78.2 | 80.6 | 73.3 | 65.7 | 65.7 | 76.2 | 71.5 | 65.4 |
| Shareholders' equity | 14.8 | 15.7 | 16.0 | 13.6 | 15.2 | 14.9 | 14.3 | 16.2 | 11.7 | 14.0 | 51.6 | 37.8 | 35.9 | 31.1 | 29.4 | 16.3 | 18.5 | 23.4 |
| Net debt (negative = net cash) | −1.3 | 0.4 | −0.3 | 6.4 | 4.8 | 2.3 | 4.3 | 2.5 | 2.5 | 1.7 | 37.2 | 38.1 | 35.3 | 34.1 | 31.2 | 41.1 | 36.9 | 34.1 |
| Quarter | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 | 2026 Q3Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Receivables | 9.0 | 9.1 | 9.7 | 9.6 | 9.6 | 7.9 | 9.1 | 9.2 |
| Inventory | 2.6 | 2.7 | 2.7 | 2.8 | 2.7 | 2.8 | 2.7 | 2.7 |
| Total current assets | 29.8 | 30.8 | 33.2 | 35.6 | 29.4 | 27.2 | 28.6 | 29.8 |
| Goodwill | 21.7 | 21.7 | 21.8 | 21.7 | 21.8 | 21.7 | 21.7 | 21.7 |
| Total assets | 92.6 | 92.4 | 94.7 | 96.9 | 90.0 | 86.5 | 87.6 | 88.8 |
| Accounts payable | 3.6 | 4.0 | 5.4 | 4.3 | 3.6 | 4.2 | 4.2 | 4.6 |
| Total current liabilities | 23.8 | 24.1 | 27.5 | 28.1 | 23.4 | 19.2 | 18.7 | 18.8 |
| Short-term debt | 2.0 | 3.6 | 4.7 | 4.5 | 2.3 | 2.3 | 1.0 | 1.0 |
| Long-term debt | 47.6 | 46.2 | 44.5 | 44.5 | 42.9 | 42.2 | 42.1 | 41.8 |
| Total debt | 49.6 | 49.7 | 49.2 | 49.0 | 45.1 | 44.5 | 43.1 | 42.9 |
| Total liabilities | 76.2 | 75.0 | 77.2 | 78.3 | 71.5 | 66.4 | 65.3 | 65.4 |
| Shareholders' equity | 16.3 | 17.4 | 17.4 | 18.6 | 18.5 | 20.1 | 22.3 | 23.4 |
Compare with peers
- Novo Nordisk A S balance sheet
- GSK plc balance sheet
- Astrazeneca PLC balance sheet
- Pfizer balance sheet
- Merck & Co. balance sheet
Head to head: BMY vs NVOBMY vs GSKAZN vs BMYBMY vs PFE
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies